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Abstract 
Although pertussis vaccines have been available for over 7 decades, countries are 
experiencing a pertussis resurgence. This study sought to establish a relationship 
between the European pertussis immunization schedule designs (with and 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended or required), which potentially influences immunity waning, and 
thus the incidence rate and epidemiologic cycles of pertussis. The theoretical 
foundation for this study was the theory of herd immunity. A quantitative 
research method was used, supported by a secondary data source. The statistical 
analysis included the use of linear regression to evaluate the relationship between 
the requirement of the vaccine and the addition of adolescent boosters on the 
incidence level and the length of the epidemiologic cycles. The study findings 
suggest that pertussis immunization, whether recommended or required, does 
have an influence on the incidence rate within the populations of the countries 
analyzed. The same influence on incidence was demonstrated in relation to 
adolescent boosters as part of the immunization schedule. A similar relationship 
was not observed between the immunization schedule requirement and design on 
the epidemiologic cycles. This study provided relevant data that contributes to 
the enhanced understanding of the relationship between the design of the 
immunization schedule on incidence. This understanding could help control the 
resurgence, reduce immune waning through adolescent boosters, enhance 
immunization schedule timing, and lower the incidence. The result would be a 
positive public health social change through improved immunization strategy. 
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Section 1: Foundation of the Study and Literature Review 
Introduction 
Pertussis is the result of a human-acquired infection by the bacterium 
Bordetella pertussis and to a much lesser extent Bordetella parapertussis, 
transmitted via airborne droplets generated from a cough or a sneeze (Bouchez & 
Guiso, 2015). B. pertussis colonizes in the respiratory tract and the toxins 
contribute to the pathogenesis of the disease (Carbonetti, 2016). Pertussis has a 
3-week incubation period prior to the first of three phases of the disease: 
catarrhal, paroxysmal, and convalescent phase, each lasting 1–2 weeks (Locht, 
2016). The catarrhal stage involves nondescript symptoms such as a sore throat, 
dry cough, runny nose, and in less than 20% of infected individuals, a fever. The 
spasmodic stage is characterized by a paroxysmal cough, episodes of cyanosis 
from coughing and vomiting. The convalescent stage is the final stage of the 
disease, which brings a reduction in the severity of the cough and other related 
symptoms (Calvert & Heath, 2017). There are also several secondary 
complications associated with pertussis, which can prove fatal in infants, such as 
pneumonia, apnea, leukocytosis, and pulmonary hypertension (Carbonetti, 
2016).  
In the early 1900s, before the development of pertussis vaccines, it was 
understood that pertussis was not just a disease affecting children but a disease 
that was also found in adults, albeit in a much milder and less acute form (Clark, 
2014). Following the development and use of whole-cell pertussis vaccines, the 
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incidence of the disease was significantly reduced. However, it was understood 
that the pertussis vaccines did not provide lifelong immunity (Clark, 2014). 
Pertussis generally occurs in episodic cycles of 3–5 years, providing evidence that 
although the incidence of pertussis can be reduced, the transmission of the 
disease can continue throughout the population (Clark, 2014).  
The purpose of vaccination for diseases like pertussis is to reduce the 
severity and mortality associated with the disease (World Health Organization 
[WHO], 2016). The causative agent of pertussis, B. pertussis, was determined in 
1906. The bacterium, B. pertussis, was utilized to create the first vaccine against 
pertussis. The vaccine created was a whole-cell vaccine (Saadatian-Elahi et al., 
2016). In 1940, clinical trial data became available, which supported the 
effectiveness of the whole-cell vaccine against pertussis (Clark, 2014). Pertussis 
whole-cell vaccines have been recommended for use in developed countries since 
the 1940s. This vaccine was eventually used globally until the 1990s when an 
acellular vaccine was developed with a safer safety profile. The acellular vaccine 
was adopted in many of the developed countries around the globe. However, 
most developing countries continue to utilize the whole-cell pertussis vaccine for 
economic reasons (Esposito & Principi, 2016). It is estimated that approximately 
70% of the countries around the globe still utilize whole-cell pertussis vaccines 
(Bouchez & Guiso, 2015). 
After the transition in some developed countries to the acellular pertussis 
vaccines, it was discovered that the immune response to the vaccine was not as 
long lasting as the pertussis whole-cell vaccine (Guiso et al., 2017). Although 
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acellular pertussis vaccines do not produce the undesired side effects that the 
pertussis whole-cell vaccines do, they are not as effective in sustaining immunity 
as the whole-cell vaccines (Guiso et al., 2017). The lack of immune efficacy is 
likely due to the difference in how immunity is established in the body (Guiso et 
al., 2017). The pertussis acellular vaccine induces an immune response, which 
involves T helper 2 response without the involvement of T memory cells. The 
pertussis whole-cell vaccine activates T helper 1 and 17 response with the 
involvement of B and T memory cells. The immunologic pathway of the whole-
cell vaccine provides longer lasting immunity (Guiso et al., 2017). 
Because pertussis was long viewed as a disease of only infants and 
preadolescent children, immunization schedule recommendations for both 
acellular and whole-cell vaccines were structured to administer the primary series 
in Year 1 of life, followed by two boosters in Year 2 and Year 3/4 (Esposito & 
Principi, 2016). While whole-cell vaccines were in use, boosters were not 
administered to adolescents and adults because the side effects of the vaccine 
were more severe in older individuals. The introduction of acellular vaccines 
allowed for the introduction of boosters beyond the primary vaccination series 
provided in infants and young children (Bouchez & Guiso, 2015).  
The structure of the immunization schedules provided a significant 
reduction in pertussis until a gradual increase of pertussis incidence was 
observed in the 1980s in areas with high pertussis vaccination rates (Esposito & 
Principi, 2016). Additionally, the incidence of pertussis diagnosed in adolescents 
and adults was increasing. In an attempt to reduce the pertussis incidence, 
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recommendations for adolescent and adult boosters were also added to the 
immunization schedules in many countries (Esposito & Principi, 2016). 
 Pertussis is a disease that remains prevalent globally despite the fact that 
vaccines have been available since the 1940s (Locht, 2016). In some developed 
areas of the globe, where the pertussis vaccines have been in use for decades, 
such as the United States, United Kingdom, and Australia, a resurgence of 
pertussis has occurred (Sealy, Belcher, & Preston, 2016). Multiple significant 
outbreaks have occurred. These outbreaks have yielded different epidemiology 
compared to prior years. The main epidemiological difference is the age of the 
individuals contracting pertussis. Since the 1990s, while still considerably high in 
infants, the adolescent incidence of pertussis has been increasing (Sealy, Belcher, 
& Preston, 2016). 
The resurgence of pertussis is a phenomenon that is occurring in both 
developed and developing countries throughout the world (Chen & He, 2017). 
The resurgence has estimated rates of infection for developed countries by up to 
12% and up to 50% in developing countries. The incidence rate for this vaccine-
preventable disease is most significant in children under the age of 2, with fatality 
rates of 0.2% in developed countries and 4% in developing countries (Chen & He, 
2017). Both developed and developing countries have observed an 
epidemiological shift in an increase of pertussis in adolescents and adults (Chen 
& He, 2017). 
Adolescents and adults are believed to be the primary source of infection 
transmission to children under the age of 2 years. Recognition of the 
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epidemiological shift in an increase of pertussis in adolescents and adults is 
significant. because adolescents and adults have been found to be the primary 
source of infection of unprotected infants (Terranella et al., 2016). This is 
because of the epidemiological shift in the increase of pertussis in adolescents 
and adults, and the immune waning associated with the implementation of 
acellular pertussis vaccines, the understanding of the potential of the relationship 
between the design and requirement of pertussis immunization schedules on 
pertussis incidence and the associated epidemiologic cycles could assist in 
controlling the pertussis resurgence, reducing immune waning, enhancing 
immunization schedules, and lowering the incidence of pertussis, thus resulting 
in positive public health social change through improved immunization strategy.  
Problem Statement 
Despite the availability of pertussis vaccines for over 70 years, countries 
are experiencing a resurgence of pertussis among their populations (Della-Torre, 
Benevides, Pereira de Melo, & Ferreira, 2015). Globally, the annual estimate of 
the incidence of pertussis is up to 40 million cases; these are associated with 
approximately 300,000 deaths (Muloiwa, Kagina, Engel, & Hussy, 2015). The 
actual worldwide incidence of pertussis has not been accurately determined 
because of the variability in the reporting and collection of the epidemiology. The 
variability in the collection of the data has a significant effect on the 
understanding of the true incidence of pertussis (Esposito & Principi, 2016).  
Another significant aspect associated with pertussis that has not been 
determined is a complete understanding of the disease pathogenesis. 
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Additionally, although the pertussis vaccines, both acellular and whole-cell, have 
been effective in reducing the incidence of pertussis, the immunological 
mechanisms of B. pertussis are not well understood (Lapidot & Gill, 2016). The 
use of the acellular pertussis vaccine has been linked to the resurgence of 
pertussis in developed countries due to evidence of immune waning. In addition 
to immune waning, there has also been an upsurge in the number of 
asymptomatic infections in adolescents, thus leading to increased transmission of 
the disease (Sealy, Belcher, & Preston, 2016). Pertussis is pervasive throughout 
the world; the true magnitude of its pervasiveness is unknown and is complicated 
due to the fact that asymptomatic pertussis infection is common in adolescents 
and adults (Sealy, Belcher, & Preston, 2016). 
Older children, adolescents, and adults can also develop the disease, but 
the illness is not as severe as it is in infants, pregnant women, and the elderly, 
who are at higher risk for contracting pertussis (Guiso, 2014). An age incidence 
trend has also emerged as part of the resurgence of pertussis. The incidence 
involving adolescents in the age range of 13–16 has surfaced as a change in the 
historical trending of the disease. Infants, mainly those less than 3 months old, 
have the highest rate of pertussis-related deaths (Centers for Disease Control and 
Prevention [CDC], 2017). The increase in the incidence of detected and 
undetected pertussis in the adolescent and adult populations, along with immune 
waning, is believed to play a significant role in the continuation of the reservoir of 
circulating pertussis, and thus in the resurgence of pertussis in countries with 
well-established vaccination rates (Esposito & Principi, 2016). 
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A review of the literature on pertussis resurgence reveals gaps in 
understanding the cause and contributing factors associated with the resurgence. 
The literature does suggest some potential causes for the resurgence of pertussis, 
such as changes in the vaccine, bacterial genetic variations in the bacterium, 
immunity waning, and pertussis vaccine effectiveness (Althouse & Scarpino, 
2015). Two additional proposed causes for the pertussis resurgence are the 
timing of initial and booster vaccination schedules (Riolo & Rohani, 2015) and 
the asymptomatic transmission of the disease caused by inadequate booster 
immunization coverage (Althouse & Scarpino, 2015).  
The use of vaccines is an essential tool to protect public health against 
pertussis. Not only do vaccines protect the immunized individual, but they also 
create a state of herd immunity that protects the population (Sabbe & 
Vandermeulen, 2016). Pertussis vaccines have played a protective role in 
reducing the incidence of pertussis. However, with the implementation of 
acellular vaccines, immunity is waning at a more rapid rate than with whole-cell 
vaccines (Sabbe & Vandermeulen, 2016). There is also a significant variation in 
pertussis primary vaccination schedules globally. The type of vaccine utilized for 
the primary series, including the mixing of vaccine types during the series, also 
varies globally (WHO, 2016). A gap identified in the literature, and the focus of 
this study, is the understanding of the potential relationship between the type of 
acellular pertussis vaccine in use and the pertussis vaccination schedule, whether 
recommended or mandatory, has as contributing factors to the country’s 
pertussis incidence and epidemiologic cycles. Additionally, the impact that a 
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country’s requirement for pertussis immunization, whether recommended or 
required, is also a gap in the literature.  
Data collected via surveillance and statistical modeling provide evidence 
that the continued use of acellular pertussis vaccines will lead to an increased 
pertussis resurgence. The resurgence increases because, as immunity wanes 
following immunization, the risk of fatality to the unimmunized children who 
may contract the disease increases (WHO, 2016). The extent, severity, and timing 
of the resurgence are not known. The factors that play a potential role in the 
resurgence of pertussis, such as vaccine type, the structure of the vaccine 
schedule, and the vaccine coverage, need to be evaluated to lower the incidence of 
pertussis and stop the resurgence of the disease (WHO, 2016).  
Purpose of the Study 
This doctoral study was to establish if there was any relationship between 
the pertussis immunization schedule design (with and without the inclusion of 
adolescent boosters) and the immunization requirement (recommended or 
required), which potentially influences immunity waning, and thus the incidence 
rate and epidemiologic cycles of pertussis within a country’s population. Multiple 
European countries with recommended and mandatory pertussis immunization 
schedules were included in the study. Immunity waning is suggested to be a 
contributing factor in the increase in pertussis incidence in both economically 
developed and developing countries (Sealy, Belcher, & Preston, 2016). This study 
provided evidence of the potential relationships associated with immunization 
schedule design and the immunization requirement on the incidence and 
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frequency of epidemiologic cycles. The study findings related to immunization 
schedule design and the immunization requirement could also be utilized by 
health professionals to address the health and medical needs of populations that 
are at an elevated risk of contracting pertussis.  
Research Questions and Hypotheses 
This study was guided by the following four e research questions: 
1. RQ1: Is there any association between the pertussis vaccine schedule 
that is required by the European country and the incidence level of 
pertussis?  The null hypothesis (H0) is that there is not an association 
between the pertussis vaccine schedule that is required by the 
European country and the incidence level of pertussis. The alternative 
hypothesis (H1) is that there is an association between the pertussis 
vaccine schedule that is required by the European country and the 
incidence level of pertussis. 
2. RQ2: Is there any association between the pertussis vaccine schedule 
that is required by the European country and the epidemiologic cycles 
of pertussis?  The null hypothesis (H0) is that there is not an 
association between the pertussis vaccine schedule that is required by 
the European country and the epidemiologic cycles of pertussis. The 
alternative hypothesis (H1) is that there is an association between the 
pertussis vaccine schedule that is required by the European country 
and the epidemiologic cycles of pertussis. 
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3. RQ3: Is there any association between the European country’s addition 
of required adolescent boosters to the pertussis vaccine schedule and 
incidence level of pertussis? The null hypothesis (H0) is that there is 
not an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
incidence level of pertussis. The alternative hypothesis (H1) is that 
there is an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
incidence level of pertussis. 
4. RQ4: Is there any association between the European country’s addition 
of required adolescent boosters to the pertussis vaccine schedule and 
the length of the epidemiologic cycles? The null hypothesis (H0) is that 
there is not an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles. The alternative hypothesis (H1) is 
that there is an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles. 
Theoretical Foundation for the Study 
 The theoretical foundation for this doctoral study was the theory of herd 
immunity, that is,  the indirect protection received by individuals who are 
susceptible to a given disease from those individuals in the population who are 
immune to the same given disease (Plans-Rubio, 2014). The theory of herd 
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immunity suggests that infectious diseases that are contracted person-to-person 
are limited when a critical proportion of the population or the herd immunity 
threshold is protected through vaccination or natural immunity to the infectious 
disease, thus reducing the potential prevalence or resurgence of the disease in the 
population (Plans-Rubio, 2014). The reduction in the incidence of infectious 
disease is termed the herd effect (Holland & Chase, 2014). If herd immunity in a 
population does not meet the required threshold, the herd effect will still provide 
a protective buffer of the population against the infectious disease (Holland & 
Chase, 2014). 
 The pertussis vaccine aids in protecting individuals who are immunized 
from contracting pertussis (Domenech de Cellès, Riolo, Magpantay, Rohani, & 
King, 2014). However, research related to the transmission effects of pertussis is 
lacking and needs to be better defined. The incidence rates in populations that 
have high pertussis vaccination rates suggest that there is a herd immunity effect 
(Domenech de Cellès et al., 2014). Additionally, in populations with high 
pertussis vaccination rates, there is data to suggest that reduced transmission, 
shorter epidemiologic cycles, and reduction in the incidence of pertussis in 
unvaccinated infants strengthens the existence of herd immunity in the 
population (Domenech de Cellès et al., 2014).  
 The primary objective of pertussis immunization programs is the 
reduction of disease and the associated mortality, and the potential 
establishment of population herd immunity (Nitsch-Osuch et al., 2013). 
Vaccination schedules for pertussis vary significantly among the countries of the 
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world (Nitsch-Osuch et al., 2013). Adherence to vaccination schedules and the 
use of appropriately timed boosters, when immunity against pertussis waning is 
suspected, are essential to the establishment of herd immunity (Nitsch-Osuch et 
al., 2013). Data from research studies have provided evidence that European 
countries need to incorporate booster vaccinations into their immunization 
schedules to strengthen individual and population protection, and the 
establishment of strong herd immunity against pertussis infection and 
transmission (Nitsch-Osuch et al., 2013). This study utilized four research 
questions to understand if there was any relationship between the pertussis 
immunization schedule design and the immunization requirement, which 
potentially influences immunity waning, and thus the incidence rate and 
epidemiologic cycles of pertussis within a country’s population. The dependent 
and independent variables linked with the research questions also helped 
establish if the vaccination schedule design, immunization requirement, and use 
of booster vaccinations provided evidence of a population herd immunity effect 
based on pertussis incidence.  
Nature of the Study 
This study utilized a quantitative research method, supported by a 
secondary data source, to help address the research questions. The quantitative 
research approach was used to evaluate the potential relationship between the 
requirement of the pertussis vaccine (recommended or required), and the 
addition of recommended or required adolescent boosters, on the incidence level 
and the length of the epidemiologic cycles of pertussis. The quantitative approach 
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used aspects of descriptive analysis, measures of central tendency, and 
correlation coefficients for the statistical analysis. Additionally, the statistical 
analysis included measures of dispersion and inferential statistics.  
The dependent variable for RQ1 was the pertussis incidence within the 
country’s population. The independent variable for RQ1 was the pertussis vaccine 
schedule required by the country. The dependent variable for RQ2 was the 
pertussis epidemiologic cycles of pertussis within the country’s population. The 
independent variable for RQ2 was the pertussis vaccine schedule required by the 
country. The dependent variable for RQ3 was the pertussis incidence level of 
pertussis within the country’s population. The independent variable for RQ3 was 
the country’s addition of required adolescent boosters to the pertussis vaccine 
schedule recommended by the country. The dependent variable for RQ4 was the 
length of the epidemiologic cycles of pertussis within the country’s population. 
The independent variable for RQ4 was the country’s addition of recommended 
adolescent boosters to the pertussis vaccine schedule required by the country. 
Literature Review Search Strategy 
 The literature review was carried out with the following databases: 
PubMed, Science Direct, CINAHL, Medline, and Google Scholar. The following 
search terms were used: pertussis,  vaccines, resurgence, schedules, boosters, 
asymptomatic, incidence, and epidemiologic cycles. The review was limited to a 
5-year timeframe, and focused on information gathered from peer-reviewed 
journals.  
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Literature Review and Related  Key Variables and/or Concepts 
Pertussis is a vaccine-preventable disease, but the incidence of the disease 
continues to rebound in countries with high vaccination rates (Esposito & 
Principi, 2016). The expert panel assembled for the 2015 Pertussis: Biology, 
Epidemiology, and Prevention Conference determined that improving current 
vaccine strategies, as well as the creation of more effective vaccines would be 
required to address the ongoing challenges with the global control of pertussis. 
The panel of experts determined that there are multiple factors associated with 
the continued elevated incidence, and in some countries, the resurgence of 
pertussis despite adequate vaccination programs. The factors identified were 
vaccine strategy, population composition, surveillance systems, and methods of 
detection (Saadatian-Elahi et al., 2016). 
Tan et al. (2015) examined the pertussis incidence trends from a global 
aspect and determined that underreporting of pertussis is a significant problem. 
Under-reporting of pertussis is most prevalent in adult and adolescent 
populations. Global under-reporting of pertussis appears to be in part associated 
with several factors, such as the type of surveillance system, the robustness of the 
surveillance system, health system infrastructure, and healthcare technological 
capabilities (Tan et al., 2015). The adolescent and adult populations are the most 
challenging to detect pertussis incidence due to the generalized characteristics 
and the lessened severity of pertussis in the adolescent and adult populations. In 
the adolescent and adult populations, pertussis presents as a persistent, but not 
15 
 
 
 
severe cough, unlike the severe illness experienced by young children and infants 
(Tan et al., 2015).  
European countries have experienced a resurgence of pertussis, as the 
other regions around the globe have, despite having established immunization 
programs and surveillance systems in place (Heiniger et al., 2016). Due to the 
multifaceted aspects of the disease dynamics associated with pertussis, the cause 
of the resurgence of pertussis in Europe and other regions of the world has not 
been established. However, it has been determined that the transmission of 
pertussis by adolescents and adults with waning pertussis immunity has caused 
the continuation of pertussis epidemiologic cycles in European countries 
(Heiniger et al., 2016).  
There are two important aspects of the available pertussis vaccines, which 
is protection from disease and infection (Locht, 2016). Recommendations based 
on current research suggest that countries who have not yet switched to the 
acellular vaccine do not make the switch to aid in better protection against 
infection and to increase disease control. It has also been recommended that until 
more effective pertussis vaccines are developed, the optimal use of current 
vaccines is needed to control infection and prevent disease (Locht, 2016). 
Gambhir et al. (2015) utilized epidemiological modeling to examine the 
recent pertussis upsurge in the United States. The modeling identified variations 
in the pertussis efficacy and immune protection duration. The study compared 
whole-cell and acellular vaccines. The study results indicated the need to perform 
more extensive modeling to examine alternative pertussis vaccination schedules, 
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to aid in addressing the resurgence. The alternate vaccination schedules would 
include adjustments to the age of vaccination, the age of booster doses, and 
cocooning strategies (Gambhir, Clark, Cauchemez, Tartof, Swerdlow, & Ferguson, 
2015). 
Choi, Campbell, Amirthalingam, Jan van Hoek, and Miller (2016) 
developed a mathematical model to examine the transmission of pertussis to gain 
an understanding of the revival of pertussis in the countries of England and 
Wales. The model also examined the potential effect of the introduction of the 
addition of a different vaccination schedule. The modeling presented data that 
indicated that countries currently using a pertussis whole-cell vaccine should not 
transition to an acellular vaccine unless enhanced vaccination strategies are 
developed. Additionally, the modeling indicated that a more effective pertussis 
vaccine is needed to lessen the resurgence (Choi, Campbell, Amirthalingam, Jan 
van Hoek, & Miller, 2016).  
Believing that the change from a whole-cell to an acellular vaccine has 
influenced the pertussis resurgence in the country of New Zealand, Radke, 
Petousis-Harris, Watson, Gentles, and Turner (2016) examined the effectiveness 
of the acellular vaccine schedule utilized in New Zealand. The authors found that 
the vaccine protection from the immunization schedule only provides protection 
through age four. The study concluded that introducing a pertussis vaccine 
booster at age six would enhance childhood immunity (Radke, Petousis-Harris, 
Watson, Gentles, & Turner, 2016). 
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Definitions 
 Adolescent Booster: Supplemental doses of a vaccine intended to boost the 
immunity of an adolescent (U.S. Health and Human Services, 2018). 
 Asymptomatic Infection: Infection occurring with apparent symptoms 
(U.S. Health and Human Services, 2018). 
Epidemiologic Cycle: The length of time between the increase of pertussis 
incidence over time in a given population (Domenech de Celles, Magpantay,  
King,  & Rohani,  2016).  
 Herd Immunity: The indirect protection received by individuals who are 
susceptible to a given disease from those individuals in the population who have 
immunity to the same given disease (Plans-Rubio, 2014). 
 Immunization Schedule: Is a schedule of immunization requirements 
based on age, number of doses, and timing of the doses of a vaccine (Kim, D, 
Bridges,  & Harriman, 2015).  
 Pertussis Incidence: The quantity of new pertussis cases reported 
associated with a population during a defined period (U.S. Health and Human 
Services, 2018). 
Pertussis Resurgence: The increase in the incidence of reported pertussis 
cases (Kilgore, Salin, Zervos, & Schmitt, 2016). 
 Pertussis Acellular Vaccine: A vaccine made from purified components of 
inactivated bacteria Bordetella pertussis (Kilgore, Salin, Zervos, & Schmitt, 
2016). 
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 Pertussis Whole-Cell Vaccine: A vaccine made from a suspension of whole 
inactivated Bordetella pertussis bacteria (Kilgore, Salin, Zervos, & Schmitt, 
2016). 
 Recommended Immunization: Vaccines that are recommended, but not 
required by law for specific populations as part of the national immunization 
program of a given country (Haverkate et al., 2012). 
 Required Immunization: Vaccines that are required by law for specific 
populations as part of the national immunization program of a given country 
(Haverkate et al., 2012). 
 Waning Immunity: The reduction or loss of immune protecting antibodies 
over a period of time (U.S. Health and Human Services, 2018). 
Assumptions 
 The data associated with the data set utilized for this study were presumed 
to be accurate. The database contained data from 1980 to 2017 and was updated 
annually. The database utilized for the study was the most up-to-date available.  
Scope and Delimitations 
 The WHO database, Vaccine-Preventable Disease: Monitoring System 
2018 Global Summary (WVPDMSGS), contains global vaccination data. 
European countries utilizing acellular pertussis vaccines with recommended and 
required immunization schedules were chosen for the study. Understanding any 
identified differences in pertussis incidence and epidemiologic cycles potentially 
associated with immunization schedules helped develop an awareness of the 
19 
 
 
 
potential need for the adjustment of immunization schedule strategies to 
strengthen waning immunity.  
Social Significance  
This study was expected to provide data to help explain the factors that 
may be contributing to the resurgence and persistence of pertussis; the data 
generated from this doctoral study was expected to provide an enhanced 
understanding of the relationship between the design and requirement of the 
immunization schedule on pertussis incidence and epidemiologic cycles. 
Understanding the potential of this relationship could assist in controlling the 
pertussis resurgence, reduce immune waning, enhance immunization schedules, 
and lower the incidence of pertussis resulting in positive social change through 
improved immunization strategy. Specifically, the study outcomes could be 
applied in the field of public health through improvements in immunization 
schedules and strategies to be used in vaccination programs, and then 
appropriately applied within economically developed and developing countries.  
Summary   
Pertussis vaccines have been available for more than 70 years, but 
countries around the globe are experiencing a resurgence of pertussis among 
their populations (Della-Torre, Benevides, Pereira de Melo, & Ferreira, 2015). 
The global annual estimate of the incidence of pertussis is more than 40 million 
cases; these are associated with approximately 300,000 deaths (Muloiwa, Kagina, 
Engel, & Hussy, 2015). The true worldwide incidence of global pertussis has not 
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been determined because of the significant variability in the reporting and 
collection of epidemiologic data (Esposito & Principi, 2016).  
Following the development and use of whole-cell pertussis vaccines, the 
incidence of pertussis was significantly reduced. However, it was understood that 
these vaccines did not provide lifelong immunity (Clark, 2014). Pertussis 
generally occurs in cycles of 3 to 5 years, providing evidence that although the 
incidence of pertussis can be reduced, the transmission of the disease can 
continue throughout the population (Clark, 2014). 
A gap identified in the literature was the understanding of the potential 
relationship between the type (acellular or whole-cell) of pertussis vaccine in use, 
and whether the pertussis vaccination schedule has contributing factors to the 
country’s pertussis incidence and epidemiologic cycle. An additional gap in the 
literature associated with pertussis was the impact of a country’s pertussis 
vaccination requirement, whether recommended or required, on the country’s 
pertussis incidence and epidemiologic cycles. Therefore, the aim of this study was 
to establish whether there is any relationship between the pertussis 
immunization schedule design (with and without the inclusion of adolescent 
boosters) and the immunization requirement (recommended or required), which 
could influence immunity waning, and thus the incidence rate and epidemiologic 
cycles of pertussis within the country’s population.  
Multiple European countries with recommended and mandatory pertussis 
immunization schedules were included in the study. The study used a 
quantitative research method, supported by a secondary data source, to help 
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address the research questions. A quantitative research approach was used to 
evaluate the potential relationship between the requirement of the pertussis 
vaccine (recommended or required) and the addition of recommended or 
required adolescent boosters on the incidence level and the length of the 
epidemiologic cycles of pertussis. This doctoral study provided data to help 
explain the factors that may be contributing to the resurgence and persistence of 
pertussis. Additionally, the data generated from this doctoral study provided an 
enhanced understanding of the relationship between the design and requirement 
of the immunization schedule on pertussis incidence and epidemiologic cycles. 
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Section 2: Research Design and Data Collection 
Introduction 
 The purpose of this section is to describe and outline the research design 
and method of data collection. The research design examines the potential 
association between the pertussis immunization schedule design (with and 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended or required). The association of the vaccine schedule and 
immunization requirement potentially influence immunity waning, and thus the 
incidence rate and epidemiologic cycles of pertussis within the country’s 
population. Multiple European countries with recommended and mandatory 
pertussis immunization schedules are included in the study.  
Research Design and Rationale 
The secondary data source that was utilized in this study was the 
WVPDMSGS. The selected database was developed by the WHO. The database 
offers global pertussis data associated with population data, reported cases, 
vaccination rates, immunization schedules, and immunization indicators (WHO, 
2017). The data associated with the recommendation or requirement of pertussis 
immunization schedules was collected from the European Centre for Disease 
Prevention and Control Vaccine Scheduler (European Centre for Disease 
Prevention and Control, 2018). 
The WVPDMSGS was selected because it provides the population 
information required to answer the research questions at the country level. The 
European countries chosen to be assessed in the doctoral study were based on 
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their requirement for pertussis immunization vaccine used within the country 
and the inclusion of adolescent boosters in the vaccine schedule. All of the 
European countries chosen used acellular pertussis vaccines.  
The WVPDMSGS database was used to examine this study’s four research 
questions. Each of the four research questions involved the examination of the 
required (mandatory by law) immunization schedule or the recommended 
(voluntary) immunization schedule of the European countries involved in the 
study. The dependent variable for RQ1 was the pertussis incidence within the 
country’s population. The independent variable for RQ1 was the pertussis vaccine 
schedule required by the country. The dependent variable for RQ2 was the 
pertussis epidemiologic cycles of pertussis within the country’s population. The 
independent variable for RQ2 was the pertussis vaccine schedule required by the 
country. The dependent variable for RQ3 was the pertussis incidence level of 
pertussis within the country’s population. The independent variable for RQ3 was 
the country’s addition of required adolescent boosters to the pertussis vaccine 
schedule recommended by the country. The dependent variable for RQ4 was the 
length of the epidemiologic cycles of pertussis within the country’s population. 
The independent variable for RQ4 was the country’s addition of recommended 
adolescent boosters to the pertussis vaccine schedule required by the country. 
Methodology 
Population 
 The population consisted of European countries utilizing pertussis 
acellular vaccines. The countries were selected based on their recommendations 
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or required pertussis immunization schedules. Additionally, countries 
recommending and requiring adolescent pertussis vaccines were included.  
Sampling Procedure 
Secondary data from the WVPDMSGS database was used for this doctoral 
study. The WVPDMSGS database contains immunization data that is assembled 
and assessed on an annual basis. The WHO works in partnership with the United 
Nations Children’s Fund (UNICEF) to collect the data that populates the 
WVPDMSGS database (WHO, 2011).  
The primary source of the data for the database is collected using joint 
reporting forms that were created in collaboration with WHO, UNICEF, and the 
ministries of health from participating member states. The forms were created to 
collect information associated with the participating countries' immunization 
coverage, reported vaccine-preventable diseases, immunization schedules, and 
immunization system performance indicators (WHO, 2011). Additional data 
included in the database is collected from the published literature that is 
evaluated by WHO, UNICEF, and experts from the locations referenced in the 
literature, UNICEF historical databases, and surveys provided by participating 
ministries of health (WHO, 2011). 
The data were sampled based on the date range and countries selected to 
be evaluated as part of the doctoral study. A power analysis was performed to 
determine the sample size required to assure statistical significance. The data was 
not be altered from the reported values. IRB approval through Walden University 
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to utilize the secondary data was obtained prior to evaluating the data (12-24-18-
0543758).  
Instrumentation and Operationalization of Constructs 
This doctoral study used secondary data from a public database. The 
database used was the WVPDMSGS database. The database data was collected 
and verified by WHO, UNICEF, and select ministries of health and is updated on 
a yearly basis. The process of establishing the validity and reliability of the data 
used to populate the database was performed by WHO, UNICEF, local experts, 
and external reviewers.  
The WVPDMSGS database was established in 2010 following a 
retrospective review by WHO and UNICEF of immunization data starting in the 
year 2000. The data being evaluated extended back to 1980 (WHO, 2011). The 
2010 database was created to establish an accurate estimate of the immunization 
coverage of a variety of vaccine-preventable diseases (Burton et al., 2009). Since 
2010, the database has been updated on an annual basis (WHO, 2011). WHO 
and UNICEF collaborate with the individual countries, working closely with them 
to understand and improve the accuracy and quality of the data (Burton et al., 
2009). 
The data collected for the database came from four primary sources, 
official immunization data reported from WHO member states, UNICEF historic 
immunization database, published literature, and surveys from ministries of 
health (WHO, 2011). The data were evaluated for a true reflection of 
immunization performance and potentially compromised data, as well as for 
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potential biases, factualness of the information, and to verify that the data was 
obtained from reliable sources (WHO, 2011). The method used to evaluate and 
compile the data involves eight principles, which are: using evidence-based data, 
country-specific data, consistent patterns and trends, local expertise, no 
averaging of data, no smoothing of data, no 100% coverage of data, and 
determining the proportion of live births utilizing a mathematical model (WHO, 
2011).  
The process of data evaluation was conducted in multiple steps. The data 
is first collected and then was reviewed by WHO and UNICEF to check for 
accuracy against the reported national data, assessing if the data is compromised 
or inaccurate in regards to immunization coverage (WHO, 2011). Discrepancies 
are handled by contacting the reporting country to investigate discrepancies. 
Whenever possible, WHO and UNICEF work with experts from the reporting 
countries. Based on the official data reviewed and evaluated, draft estimates of 
immunization coverage are calculated (WHO, 2011). 
The next step in the data evaluation process was to have the data reviewed 
by national authorities. The national authorities review the data for accuracy 
based on local knowledge and expertise. Following the national authority review, 
the draft estimates are revised by the WHO and UNICEF (WHO, 2011). The last 
step in the data evaluation process was to have the data undergo an external 
review by immunization experts with specialized expertise in immunization 
systems and methodology associated with surveys. Any additional revisions, as an 
outcome of the external review, are performed by WHO and UNICEF, and the 
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data was then added to the database and disseminated for public access (WHO, 
2011). 
The operationalization of the variables collected for the doctoral study is 
outlined in Table 1. The variable data was obtained from the WVPDMSGS 
database. The nominal variables are immunization schedule recommended, 
immunization schedule required, adolescent boosters recommended, and 
adolescent boosters required. The categorical variables are pertussis incidence 
and length of the epidemiologic cycle. 
 
Table 1 
Operationalization of Variables Collected from WHO Vaccine-Preventable 
Disease: Monitoring System 2018 Global Summary database 
_______________________________________________________ 
Variable                                                     Values               Research Question    
_______________________________________________________ 
Pertussis incidence                                   Value                          RQ 1, 3 
Immunization schedule required          Yes/No                       RQ 1, 2 
Length of epidemiologic cycle                Value                          RQ 2, 4 
Adolescent boosters required                 Yes/No                      RQ 3, 4 
_______________________________________________________ 
 
Data Analysis Plan 
The intention of the doctoral study was to establish if there was any 
relationship between the pertussis immunization schedule design (with versus 
28 
 
 
 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended versus required), which potentially influences immunity waning, 
and thus the incidence rate and epidemiologic cycles of pertussis within the 
country’s population. Data from this study were analyzed using SPSS version 24. 
SPSS version 24 was used to screen and clean the data before the data is used in 
the analysis of the research questions. The data were assessed for any missing 
variables, outliers, skewness, and to assure that the variables meet the statistical 
assumptions that are associated with the statistical analysis that will be 
performed as part of the doctoral study.  
The data analyzed from the WVPDMSGS database focused on European 
countries utilizing acellular pertussis vaccines. The quantitative research 
approach was used to evaluate the potential relationship between the 
requirement of the pertussis vaccine (recommended versus required) and the 
addition of recommended versus required adolescent boosters on the incidence 
level and the length of the epidemiologic cycles of pertussis. The quantitative 
approach used aspects of descriptive analysis, measures of central tendency, and 
correlation coefficients for the statistical analysis. The qualitative approach also 
included a determination of the P-value, confidence intervals, mean, standard 
deviation, and F-test as specific tests of statistical significance. Additionally, the 
statistical analysis included linear regression to evaluate the potential 
relationship between the requirement of the pertussis vaccine (recommended 
versus required) and the addition of recommended versus required adolescent 
boosters on the incidence level and the length of the epidemiologic cycles of 
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pertussis for each of the respective research questions that have been broken out 
into four independent questions.  
In order to understand the relationship amid the dependent variable and 
the independent variable associated with the research question, linear regression 
analysis was used to evaluate the research question. The linear regression 
analysis aided in predicting the value of the dependent variable based on the 
independent variable in order to understand the nature of the relationship 
between the variables. The linear regression analysis also assisted in 
understanding how dependent variable changes in conjunction with changes in 
the independent variable associated with the research question. The results of the 
linear regression analysis were interpreted by examining the correlation and 
direction of the research data, evaluating the best fitting line, and assessing the 
strength of the relationship between the variables. Specifically, the data analysis 
will involve determining and assessing the linear regression equation, the 
coefficient of the multiple determination (R2), the significance level, and the 
confidence intervals. This statistical approach was applied to all four research 
questions.  
Due to undiscernible differences in the outcome of the linear regression as 
it relates to the independent variables from the research questions analyzed via 
linear regression, ANOVA was utilized to determine if there is a significant 
difference between the independent variables. The ANOVA allowed for a 
potential determination of the variance between the variables by comparing the 
means of the independent variables. Specifically, the descriptive statistics, such 
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as the mean, standard deviation, standard error, and confidence intervals were 
evaluated. Additionally, the Sum of Squares, Mean Square, and significance levels 
were determined to aid in the analysis. This additional statistical approach was 
applied to all four research questions. 
RQ1: Is there any association between the pertussis vaccine schedule that 
is required by the European country and the incidence level of pertussis?  The 
null hypothesis (H0) is that there is not an association between the pertussis 
vaccine schedule that is required by the European country and the incidence level 
of pertussis. The alternative hypothesis (H1) is that there is an association 
between the pertussis vaccine schedule that is required by the European country 
and the incidence level of pertussis. The dependent variable for RQ1 is the 
pertussis incidence (number of reported cases) within the country’s population. 
The independent variable for RQ1 is the pertussis vaccine schedule required by 
the country (Yes/No). The research question was analyzed with linear regression 
to determine a potential relationship between the independent and dependent 
variables. The statistical analysis included a determination of the P-value, 
confidence intervals, mean, standard deviation, and F-test as specific tests of 
statistical significance. ANOVA was applied to determine if there was a difference 
between the independent variables from the research questions analyzed via 
Linear regression. 
RQ2: Is there any association between the pertussis vaccine schedule that 
is required by the European country and the epidemiologic cycles of pertussis?  
The null hypothesis (H0) is that there is not an association between the pertussis 
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vaccine schedule that is required by the European country and the epidemiologic 
cycles of pertussis. The alternative hypothesis (H1) is that there is an association 
between the pertussis vaccine schedule that is required by the European country 
and the epidemiologic cycles of pertussis. The dependent variable for RQ2 is the 
pertussis epidemiologic cycles (length of time between spikes in incidence) of 
pertussis within the country’s population. The independent variable for RQ2 is 
the pertussis vaccine schedule required by the country (Yes/No). The research 
question was analyzed with linear regression to determine a potential 
relationship between the independent and dependent variables. The statistical 
analysis included a determination of the P-value, confidence intervals, mean, 
standard deviation, and F-test as specific tests of statistical significance. ANOVA 
was applied to determine if there was a difference between the independent 
variables from the research questions analyzed via Linear regression. 
RQ3-Quantitative: Is there any association between the European 
country’s addition of required adolescent boosters to the pertussis vaccine 
schedule and incidence level of pertussis. The null hypothesis (H0) is that there is 
not an association between the European country’s addition of required 
adolescent boosters to the pertussis vaccine schedule and the incidence level of 
pertussis. The alternative hypothesis (H1) is that there is an association between 
the European country’s addition of required adolescent boosters to the pertussis 
vaccine schedule and the incidence level of pertussis. The dependent variable for 
RQ3 is the pertussis incidence level of pertussis (number of reported cases) 
within the country’s population. The independent variable for RQ3 is the 
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country’s addition of required adolescent boosters to the pertussis vaccine 
schedule recommended by the country (Yes/No). The research question was 
analyzed with linear regression to determine a potential relationship between the 
independent and dependent variables. The statistical analysis included a 
determination of the P-value, confidence intervals, mean, standard deviation, and 
F-test as specific tests of statistical significance. ANOVA was applied to 
determine if there was a difference between the independent variables from the 
research questions analyzed via Linear regression. 
RQ4: Is there any association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the length of 
the epidemiologic cycles. The null hypothesis (H0) is that there is not an 
association between the European country’s addition of required adolescent 
boosters to the pertussis vaccine schedule and the length of the epidemiologic 
cycles. The alternative hypothesis (H1) is that there is an association between the 
European country’s addition of required adolescent boosters to the pertussis 
vaccine schedule and the length of the epidemiologic cycles. The dependent 
variable for RQ4 is the length of the epidemiologic cycles (length of time between 
spikes in incidence) of pertussis within the country’s population. The 
independent variable for RQ4 is the country’s addition of recommended 
adolescent boosters to the pertussis vaccine schedule required by the country 
(Yes/No). The research question was analyzed with linear regression to 
determine a potential relationship between the independent and dependent 
variables. The statistical analysis included a determination of the P-value, 
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confidence intervals, mean, standard deviation, and F-test as specific tests of 
statistical significance. ANOVA was applied to determine if there was a difference 
between the independent variables research questions analyzed via linear 
regression. 
Threats to Validity 
 This doctoral study has potential threats to the internal and external 
validity of the data being used to assess the research questions. Some of the 
potential internal validity threats are associated with the data contained in the 
WVPDMSGS database. Although the data was evaluated for accuracy and 
reliability, the entry of the data into the database and the aggregation of the data 
from the various reporting sources can be a potential threat to validity if they are 
not performed per the WHO and UNICEF prescribed principles. Additionally, the 
validity of the data could also be compromised if adequate reviews of the data are 
not performed by the WHO, UNICEF, local experts, and external reviewers.  
External validity threats also exist associated with the WVPDMSGS 
database. External threats to the validity of the data being used to assess the 
research questions are the accuracy of the reporting and calculation of the 
immunization coverage from the participating member states. Additionally, 
biases can be created if the participating member states fail to report portions of 
the population, or over or underestimate the vaccination coverage and incidence 
of the vaccine-preventable diseases.  
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Ethical Procedures 
Walden University IRB approval was obtained to use the public 
WVPDMSGS secondary data for this doctoral study. The data contained in the 
WVPDMSGS does not include any data that is required to be de-identified. The 
data was handled in an ethical manner during the statistical evaluation. All of 
Walden University's ethical procedures were followed during the statistical 
analysis of the doctoral study data. Following the statistical analysis of the data in 
SPSS, and completion of the doctoral study, the data will be protectively stored in 
the SPSS format, along with a copy of the WVPDMSGS database for the 
prescribed period under Walden University policy.  
Summary 
The research design utilized in this doctoral study examined the potential 
association between the pertussis immunization schedule design (with and 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended or required). The secondary data source that was used in the 
doctoral research study was the WVPDMSGS.  
The study population consisted of European countries utilizing pertussis 
acellular vaccines. The countries were selected based on their recommendations 
or required pertussis immunization schedules. Additionally, countries 
recommending and requiring adolescent pertussis vaccines were included. The 
study hypotheses were evaluated via SPSS version 24 software. The four research 
questions explored were (a) is there any association between the pertussis 
vaccine schedule that is required by the European country and the incidence level 
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of pertussis, (b) is there any association between the pertussis vaccine schedule 
that is required by the European country and the epidemiologic cycles of 
pertussis, (c) is there any association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and incidence level 
of pertussis, and (d) is there any association between the European country’s 
addition of required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles. 
A quantitative research approach was used to evaluate the potential 
relationship between the requirement of the pertussis vaccine (recommended or 
required) and the addition of recommended or required adolescent boosters on 
the incidence level and the length of the epidemiologic cycles of pertussis. The 
quantitative approach used aspects of descriptive analysis, measures of central 
tendency, and correlation coefficients for the statistical analysis. Additionally, the 
statistical analysis included measures of dispersion and inferential statistics.  
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Section 3: Presentation of Results and Findings 
Introduction 
The aim of this doctoral study was to establish whether there was any 
relationship between the pertussis immunization schedule design (with and 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended or required), which potentially influences immunity waning, and 
thus the incidence rate and epidemiologic cycles of pertussis within the country’s 
population. The dependent variables examined in the study were the pertussis 
incidence within a country’s population and the pertussis epidemiologic cycles of 
pertussis within a country’s population. The independent variables examined 
were the pertussis vaccine schedule recommended by the country, the pertussis 
vaccine schedule required by the country, the country’s addition of recommended 
adolescent boosters to the pertussis vaccine schedule, and the addition of 
required adolescent boosters to the pertussis vaccine schedule required by the 
country. The research questions and associated hypotheses are presented below. 
1. RQ1: Is there any association between the pertussis vaccine schedule that 
     is required by the European country and the incidence level of pertussis?   
H01: There is not an association between the pertussis vaccine schedule 
that is required by the European country and the incidence level of 
pertussis. H11: There is an association between the pertussis vaccine 
schedule that is required by the European country and the incidence level 
of pertussis.  
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       2. RQ2: Is there any association between the pertussis vaccine schedule that 
            is required by the European country and the epidemiologic cycles of  
            pertussis?   
H02: There is not an association between the pertussis vaccine schedule 
that is required by the European country and the epidemiologic cycles of 
pertussis.  
H12: There is an association between the pertussis vaccine schedule that is 
required by the European country and the epidemiologic cycles of 
pertussis.  
        3. RQ3: Is there any association between the European country’s addition of   
H03: There is not an association between the European country’s addition 
of required adolescent boosters to the pertussis vaccine schedule and the 
incidence level of pertussis.  
H13: There is an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
incidence level of pertussis.  
        4. RQ4: Is there any association between the European country’s addition of    
H04: There is not an association between the European country’s addition 
of required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles. 
H14: There is an association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles.  
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This section outlines the presentation of the results and findings of the 
doctoral study. In addition to the introduction, which describes the aim of the 
doctoral study, research questions, and the associated hypotheses, the section 
provides a description of the data collection, and the secondary data set used to 
answer the doctoral study research questions. Additionally, the results obtained 
from the linear regression analysis are described and discussed for each of the 
research questions. Lastly, the data analysis findings and interpretations are 
summarized.  
Data Collection of Secondary Dataset 
Secondary data from the WVPDMSGS database was used to explore the 
research questions associated with this doctoral study. The WVPDMSGS 
database contains immunization data that is assembled and assessed on an 
annual basis. The WHO works in partnership with UNICEF to collect the data 
that populates the WHO Vaccine-Preventable Disease: Monitoring System Global 
Summary database (WHO, 2011).  
The primary source of the data for the database is collected using joint 
reporting forms that were created in collaboration with WHO, UNICEF, and the 
ministries of health from participating member states. The forms were created to 
collect information associated with the participating country's immunization 
coverage, reported vaccine-preventable diseases, immunization schedules, and 
immunization system performance indicators (WHO, 2011). Additional data 
included in the database is collected from the published literature that is 
evaluated by WHO, UNICEF, and experts from the locations referenced in the 
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literature, UNICEF historical databases, and surveys provided by participating 
ministries of health (WHO, 2011). The database data is collected and verified by 
WHO, UNICEF, and select ministries of health and is updated on a yearly basis. 
The process of establishing validity and reliability of the data used to populate the 
database is performed by WHO, UNICEF, local experts, and external reviewers. 
The first stage in the evaluation of the secondary data from the 
WVPDMSGS database was to identify which European Union countries require 
pertussis immunization schedule, and which European Union countries have 
recommended pertussis immunization schedules. Additionally, which European 
Union countries required, or recommended adolescent pertussis booster needed 
to be determined. The European Centre for Disease Prevention and Control 
Vaccine Scheduler was utilized to determine the recommendation or requirement 
of pertussis immunization schedules and adolescent boosters. There was a total 
of 29 European Union countries identified that had a required or recommended 
pertussis immunization schedule. Nine of the European Union countries required 
pertussis immunization schedules and 20 had recommended pertussis 
immunization schedules. 
The secondary data from the WVPDMSGS database was reviewed based 
on the identified European Union countries. The date range evaluated as part of 
the doctoral study was from 2010 to 2017, in order to stay within the last decade. 
The criteria set for missing data per country was no more than one data point 
could be missing. The criteria set for the population range was greater than one 
million people, but less than 11 million people. The countries that meet the 
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established criteria were Austria, Bulgaria, Croatia, Czech Republic, Denmark, 
Estonia, Hungary, Ireland, Latvia, Lithuania, Norway, Portugal, Slovakia, 
Slovenia, and Sweden. Of the 15 countries that meet the missing data and 
population criteria, 7 had required pertussis immunization schedules, and 8 had 
recommended pertussis immunization schedules. The incidence data for each of 
the 15 selected European Union countries were normalized by dividing the 
incidence per 100,000 people.  
The data for the epidemiologic cycles was evaluated by taking the average 
of the 8 years being evaluated for each of the 15 selected European Union 
countries and then determining the value above or below the baseline incidence 
per country. The data evaluation resulted in a data set containing 117 data 
points. The adolescent pertussis booster data was also evaluated. It was 
determined that of the seven countries that required pertussis immunization 
schedules, five of the seven required adolescent pertussis boosters. In regard to 
the eight European Union countries that recommended pertussis immunization 
schedules, six of the eight countries also had recommended adolescent pertussis 
boosters as part of the immunization schedule. The four European Union 
countries without a required or recommended adolescent European booster as 
part of the pertussis immunization schedule, were Denmark, Portugal, Croatia, 
and Latvia. The data evaluation resulted in a data set containing 86 data points. 
Analysis  
 The doctoral study statistical analysis included the use of linear regression 
to evaluate the potential relationship between the requirement of the pertussis 
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vaccine (recommended versus required) and the addition of recommended 
versus required adolescent boosters on the incidence level and the length of the 
epidemiologic cycles of pertussis for each of the respective research questions 
that have been broken out into four independent questions. Linear regression 
required an independent variable and one dependent variable to perform the 
analysis for each of the research questions.  
In order to understand the potential relationship between the dependent 
variable and the independent variable associated with the research question, 
linear regression analysis was used to evaluate the research questions. The linear 
regression analysis aided in predicting the value of the dependent variable based 
on the independent variable in order to understand the nature of the relationship 
between the variables. The linear regression analysis also assisted in 
understanding how the dependent variable changed in conjunction with changes 
in the independent variable associated with the research questions. The outcome 
of the linear regression analysis was interpreted by examining the correlation and 
direction of the research data, evaluating the best fitting line, and assessing the 
strength of the relationship between the variables. The data analysis involved 
determining and assessing the linear regression equation, the coefficient of the 
multiple determination (R2), the significance level, and the confidence intervals. 
This statistical approach was applied to all four research questions. 
ANOVA was utilized to determine if there is a significant difference 
between the independent variables associated with the research questions. The 
ANOVA allowed for the potential determination of the variance between the 
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variables by comparing the means of the independent variables. The descriptive 
statistics, such as the mean, standard deviation, standard error, and confidence 
intervals, were evaluated. Additionally, the Sum of Squares, Mean Square, and 
significance levels were determined to aid in the analysis. This statistical 
approach was applied to all four research questions. 
Results 
Research Question 1  
 The data associated with research question 1 was analyzed utilizing Linear 
regression. The research questions was:  
RQ 1: Is there any association between the pertussis vaccine 
schedule that is required by the European country and the 
incidence level of pertussis? 
The linear combination of required and recommended immunization 
schedules was found to be significantly related to pertussis incidence in the 
European countries evaluated as part of the doctoral study. The R2 = .056, F 
(1,115) = 6.78, p = .010. The Coefficient of Determination was .056, indicating 
that approximately 5.6% of the variance in the dependent variable pertussis 
incidence in the population can be accounted for by the linear relationship of the 
independent variable of required and recommended immunization schedules. 
The descriptive characteristics, linear regression model summary, ANOVA, and 
linear regression coefficients data are exhibited in Tables 2, 3, 4, and 5 below.  
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Table 2 
Descriptive Characteristics of Vaccine Schedule Type and Incidence of  Pertussis 
_______________________________________________________ 
Variable                                        N                            Mean                            Std Dev           
_______________________________________________________ 
Pertussis incidence                      117                        10.8651                         17.49083             
Required schedule                       117                             .4701                             .50125           
Recommended schedule             117                            .5299                             .50125            
_______________________________________________________ 
 
The mean of the pertussis incidence was 10.8651. The mean of the recommended 
schedule data was larger than the mean of the required schedule data by .0598.  
 
Table 3 
Linear Regression Associated with the Relationship of Vaccine Schedule Type 
and Incidence of  Pertussis  
_______________________________________________________ 
Model    N       R      Square   Adjusted R Square    Standard Error of the Estimate                       
_______________________________________________________ 
             117    .236         .056                  .047                                     17.07051 
_______________________________________________________ 
 
Table 4 
ANOVA Associated with the Relationship of Vaccine Schedule Type and 
Incidence of  Pertussis 
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_______________________________________________________
Model           Sum of Squares       df           Mean Squares             F                   Sig 
_______________________________________________________ 
Regression       1976.503              1               1976.503              6.783              .010 
 
Residual         33511.264            115               291.402 
 Total              35487.768            116 
_________________________________________ 
 
The F-Test, with a value of 6.783, indicates that the independent variables 
(required or recommended schedules) do have explanatory power over the 
dependent variable (pertussis incidence). The significance (P value) was .010, 
which is less than .05.  
 
Table 5 
Linear Regression Coefficient Associated with the Relationship of Vaccine 
Schedule Type and Incidence of  Pertussis 
_______________________________________________________ 
Model       N       Coeff Std Error     t        sig      95% Conf Lower    95% Conf Upper                    
_______________________________________________________ 
Required   117         3.162          2.604    .010          1.972                        14.498      
 
The value of t falls between the lower and upper confidence limits for both the 
recommended and required schedules. The t value was 2.604, with a 95% lower 
confidence limit of 1.972 and a 95% upper confidence limit of 14.498. The 
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coefficients had a positive relationship. The effect size was .236 indicating a small 
level of relationship. The significance (P value) was .010, which is less than .05, 
thus rejecting the null hypothesis.  
 
Research Question 2 
The data associated with Research Question 2 were analyzed via linear 
regression. The research questions was:  
RQ2: Is there any association between the pertussis vaccine schedule that 
is required by the European country and the epidemiologic cycles of 
pertussis?   
The linear combination of required and recommended immunization 
schedules was not significantly related to pertussis epidemiologic cycles in the 
European countries evaluated as part of the doctoral study. The R2 = .001, F 
(1,115) = .119, p = .731. Coefficient of Determination was .001. Therefore, the 
required or recommended immunization schedules are not a good predictor of 
the pertussis epidemiologic cycles in the European countries evaluated as part of 
the doctoral study. The descriptive characteristics, linear regression model 
summary, ANOVA, and linear regression coefficients data are exhibited in Tables 
6, 7, 8, and 9 below.  
 
Table 6 
Descriptive Characteristics of  Vaccine Schedule Type and Epidemiologic Cycles 
of Pertussis 
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_______________________________________________________ 
Variable                                        N                            Mean                            Std Dev           
_______________________________________________________ 
Pertussis cycle                             117                            .3335                        10.33511             
Required schedule                      117                            .4701                             .50125           
Recommended schedule           117                            .5299                            .50125            
_______________________________________________________ 
 
The mean of the pertussis cycle was .3335. The mean of the recommended 
schedule data was larger than the mean of the required schedule data by .0598.  
 
Table 7 
Linear Regression Associated with Vaccine Schedule Type and Epidemiologic 
Cycles of Pertussis 
_______________________________________________________ 
Model      N      R      R Square   Adjusted R Square   Standard Error of the Estimate                       
_______________________________________________________ 
               117    .032      .001                      - .008                                    10.37460 
_______________________________________________________ 
 
 
Table 8 
ANOVA Associated with the Vaccine Schedule Type and the Epidemiologic 
Cycles of Pertussis 
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_______________________________________________________ 
Model                   Sum of Squares       df           Mean Squares                 F           sig      
_______________________________________________________ 
 Regression                12.771                 1                   12.503                   .119       .731 
 Residual             12377.717                115              107.632 
 Total                    12390.488               116 
_______________________________________________________ 
 
The F-Test, with a value of .119, indicates that the independent variables 
(required or recommended schedules) do not have explanatory power over the 
dependent variable (pertussis cycle). The significance (P value) was .731, which is 
greater than .05.  
 
Table 9 
Linear Regression Associated with Vaccine Schedule Type and Epidemiologic 
Cycles of Pertussis 
_______________________________________________________ 
Model          N     Coeff Std Error      t       sig       95% Conf Lower    95% Conf Upper                    
_______________________________________________________ 
Required    117          1.922            .344    .731             -3.145                   4.468 
_______________________________________________________ 
The value of t falls between the upper and lower confidence limits for both the 
recommended and required schedules. The t-value was .344, with a 95% lower 
confidence limit of -3.145 and a 95% upper confidence limit of 4.468. The 
coefficients had a positive relationship. The effect size was .032 indicating a small 
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relationship. The significance (P value) was .731, which is greater than .05, thus 
not rejecting the null hypothesis. 
 
Research Question 3 
The data associated with Research Question 3 was analyzed utilizing 
Linear regression. The research questions was:  
RQ3: Is there any association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and 
incidence level of pertussis? 
The linear combination of the addition of a required or recommended 
adolescent booster was significantly related to pertussis incidence in the 
European countries evaluated as part of the doctoral study. The R2 = .063, F 
(1,84) = 5.680, p = .019.  The coefficient of determination was .063, indicating 
that approximately 6.3% of the variance of the dependent variable pertussis 
incidence in the population can be accounted for by the linear combination of the 
independent variable of required and recommended adolescent boosters. The 
descriptive characteristics, linear regression model summary, ANOVA, and linear 
regression coefficients data are exhibited in Tables 10, 11, 12, and 13 below.  
 
Table 10 
Descriptive Characteristics Associated with Adolescent Booster Schedule Type 
and Incidence of Pertussis  
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_______________________________________________________ 
Variable                                        N                            Mean                            Std Dev 
_______________________________________________________ 
Pertussis incidence                      86                          12.4801                         19.60548             
Required schedule                       86                              .470                                .502           
Recommended schedule             86                              .530                                .502            
_______________________________________________________ 
 
The mean of the pertussis incidence was 12.4801. The mean of the recommended 
schedule data was larger than the mean of the required schedule data by .060.  
 
Table 11 
Linear Regression Associated with Adolescent Booster Schedule Type and 
Incidence of Pertussis  
_______________________________________________________ 
Model    N      R      R Square   Adjusted R Square    Standard Error of the Estimate                       
_______________________________________________________ 
              86     .252       .063                 .052                                      19.08712 
_______________________________________________________ 
 
Table 12 
ANOVA Data Associated with Adolescent Booster Schedule Type and Incidence 
of Pertussis  
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_______________________________________________________ 
Model                    Sum of Squares       df           Mean Squares             F                Sig 
_______________________________________________________ 
 Regression              2069.147              1               2069.147               5.680            .019 
 Residual                30602.723             84                364.318 
 Total                       32671.870            85 
 
The F-Test, with a value of 5.680, indicates that the independent variables 
(required or recommended schedules) do have explanatory power over the 
dependent variable (booster incidence). The significance (P value) was .019, 
which is less than .05.  
 
 
Table 13 
Linear Regression Associated with Adolescent Booster Schedule Type and 
Incidence of Pertussis  
_______________________________________________________ 
Model          N    Coeff Std Error     t         sig    95% Conf Lower    95% Conf Upper                    
_______________________________________________________ 
 
Required    86        4.126            2.383     .019           1.628                    18.040 
_______________________________________________________ 
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The value of t falls between the upper and lower confidence limits for both the 
recommended and required schedules. The t-value was 2.83, with a 95% lower 
confidence limit of 1.628 and a 95% upper confidence limit of 18.040. The 
coefficients had a positive relationship. The effect size was .252 indicating a small 
relationship. The significance (P value) was .019, which is less than .05, thus 
rejecting the null hypothesis. 
 
Research Question 4 
The data associated with Research Question 4 was analyzed utilizing 
European Center. The research question was:  
RQ 4: Is there any association between the European country’s addition of 
required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles? 
The linear combination of the addition of a required or recommended 
adolescent booster was not significantly related to pertussis epidemiologic cycles 
in the European countries evaluated as part of the doctoral study. The R2 = .001, 
F (1,84) = .120, p = .730. coefficient of determination was .001. Therefore, the 
required or recommended adolescent boosters are not a good predictor of the 
pertussis epidemiologic cycles in the European countries evaluated as part of the 
doctoral study. The descriptive characteristics, linear regression model summary, 
ANOVA, and linear regression coefficients data are exhibited in Tables 14, 15, 16, 
and 17 below.  
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Table 14 
Descriptive Characteristics Associated with Adolescent Booster Schedule Type 
and Length of Epidemiologic Cycles 
_______________________________________________________ 
Variable                                          N                            Mean                            Std Dev           
_______________________________________________________ 
 
Pertussis Booster Cycle               86                           .4643                            11.51829             
Required schedule                       86                            .470                                  .502          
Recommended schedule            86                            .530                                  .502        
_______________________________________________________ 
    
The mean of the pertussis cycle was .4643. The mean of the recommended 
schedule data was larger than the mean of the required schedule data by .060.  
 
Table 15 
Linear Regression Associated with Adolescent Booster Schedule Type and 
Length of Epidemiologic Cycles 
_______________________________________________________ 
Model    N        R      R Square   Adjusted R Square   Standard Error of the Estimate                       
_______________________________________________________ 
              86      .038        .001               -.010                                     11.57836 
_______________________________________________________ 
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Table 16 
ANOVA Associated with Adolescent Booster Schedule Type and Length of the 
Epidemiologic Cycles 
_______________________________________________________ 
Model                       Sum of Squares       df           Mean Squares             F               Sig 
_______________________________________________________ 
Regression                  16.503                   1                 16.121                .120             .730 
Residual                11260.907                84               134.058 
 Total                     11277.028                 85  
_______________________________________________________ 
 
The F-Test, with a value of .120, indicates that the independent variables 
(required or recommended schedules) do not have explanatory power over the 
dependent variable (pertussis booster cycle). The significance (P value) was .730, 
which is greater than .05, thus not rejecting the null hypothesis. 
 
Table 17 
Linear Regression Associated with Adolescent Booster Schedule Type and 
Length of Epidemiologic Cycles 
_______________________________________________________ 
Model         N      Coeff Std Error    t        sig       95% Conf Lower    95% Conf Upper                    
_______________________________________________________ 
Required    86         2.503             .347    .730           -4.110                       5.846 
_______________________________________________________ 
 
54 
 
 
 
The value of t falls between the upper and lower confidence limits for both the 
recommended and required schedules. The t-value was .347, with a 95% lower 
confidence limit of -4.110 and a 95% upper confidence limit of 5.846. The 
coefficients had a positive relationship. The effect size was .038 indicating a small 
relationship. The significance (P value) was .730, which is greater than .05, thus 
accepting the null hypothesis. 
Summary 
 The study findings from Research Question 1 suggests that the pertussis 
immunization, whether recommended or required, does have an influence on the 
incidence rate of pertussis within the populations of European countries analyzed 
as part of this doctoral study. The same influence on pertussis incidence was 
demonstrated within the populations of European countries analyzed as part of 
this doctoral study related to the recommended or required adolescent boosters 
that were part of the pertussis immunization schedule. This influence was 
demonstrated through Research Question 3.  
The doctoral study data also revealed via Research Question 2 that the 
pertussis immunization, recommended or required, does not have a relationship 
with the epidemiologic cycle of pertussis within the populations of European 
countries analyzed as part of the doctoral study. The same lack of relationship on 
the epidemiologic cycle of pertussis was demonstrated via Research Question 4 
within the populations of European countries analyzed as part of this doctoral 
study related to recommended or required adolescent boosters as part of the 
pertussis immunization schedule. 
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The next section of this doctoral study examines the interpretation of the 
results of the Four research questions. Additionally, an overview of the study 
limitations, recommendations for future research, implications for professional 
practice, and social change are presented. Lastly, Section 4 provides a conclusion 
of the findings of this doctoral study.  
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Section 4: Application of Professional Practice and Implications for Social 
Change 
Introduction 
The purpose of this doctoral study was to establish if there is any 
relationship between the pertussis immunization schedule design (with and 
without the inclusion of adolescent boosters) and the immunization requirement 
(recommended or required), which potentially influences immunity waning and 
thus the incidence rate and epidemiologic cycles of pertussis within a country’s 
population. Multiple European countries with recommended and mandatory 
pertussis immunization schedules were included in this study. The findings 
suggest that there is evidence of potential relationships associated between the 
immunization schedule and the immunization requirement on the incidence of 
pertussis. The same relationship was not observed between the epidemiologic 
cycles, the inclusion of adolescent boosters, and the incidence of pertussis.  
Interpretation of Findings 
The findings of this study via Research Questions 1 and 3 supported two of 
the research studies discussed in the section, Literature Review Related to Key 
Variables and/or Concepts, which mathematically modeled the effectiveness of 
acellular immunization strategies. Gambhir et al. (2015) utilized epidemiological 
modeling to examine the recent pertussis upsurge in the United States. The 
modeling identified variations in pertussis efficacy and immune protection 
duration of acellular vaccines. The results of the modeling pointed to the 
potential immune waning of acellular vaccines, and the fact that booster doses 
57 
 
 
 
added to the immunization schedules may help reduce epidemics, thus lowering 
pertussis incidence (Gambhir, Clark, Cauchemez, Tartof, Swerdlow, & Ferguson, 
2015). 
The other mathematical modeling study was performed by Choi, 
Campbell, Amirthalingam, Jan van Hoek, and Miller (2016), who developed a 
mathematical model to examine the transmission of pertussis to understand the 
revival of pertussis in the countries of England and Wales. The results of the 
mathematical modeling indicated that the protection of the acellular vaccines did 
not appear as effective as the original whole-cell vaccine, thus creating an 
immune waning. The modeling predicted that if an adolescent booster were 
added to the immunization schedule, the pertussis incidence in infants could be 
lowered (Choi, Campbell, Amirthalingam, Jan van Hoek, & Miller, 2016).  
The study evaluated the incidence and epidemiologic cycles of 15 
European countries in relation to the required or recommended immunization 
schedule and required or recommended inclusion of an adolescent booster. The 
countries that met the established criteria were Austria, Bulgaria, Croatia, Czech 
Republic, Denmark, Estonia, Hungary, Ireland, Latvia, Lithuania, Norway, 
Portugal, Slovakia, Slovenia, and Sweden. The outcome of the linear regression 
analysis was interpreted by determining and assessing the linear regression 
equation, the coefficient of the multiple determination (R2), the significance level, 
and the confidence intervals. 
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Research Question 1  
The data associated with Research Question 1 were analyzed utilizing 
linear regression. The outcome of the linear regression analysis revealed that the 
null hypothesis, which was that no association between the pertussis vaccine 
schedule that is required or recommended by the European country and the 
incidence level of pertussis be rejected. The alternative hypothesis—that there 
was an association between the pertussis vaccine schedule that is required or 
recommended by the European country and the incidence level of pertussis—was 
supported by the results. Although there was not a strong linear relationship 
between the required or recommended immunization schedules and the 
incidence of pertussis,  data analysis found that there was a significant 
relationship between the independent variable and the dependent variable.  
The linear combination of required and recommended immunization 
schedules was found to be significantly related to pertussis incidence in the 
European countries evaluated as part of the doctoral study. The Coefficient of 
Determination was .056, indicating that approximately 5.6% of the variance in 
the dependent variable pertussis incidence in the population can be accounted for 
by the linear relationship of the independent variable of required and 
recommended immunization schedules. This relationship supports the work of 
Gambhir et al. (2015), whose study results indicated the need to perform more 
extensive modeling to examine alternative pertussis vaccination schedules, to aid 
in addressing the resurgence. This doctoral study confirmed a relationship 
between the schedule type and the incidence of pertussis, which also supported 
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the Locht (2016) study results.  Locht (2016) recommended that until more 
effective pertussis vaccines are developed, the optimal use of current vaccines is 
needed to control infection and prevent disease.  
The theory of herd immunity suggests that infectious diseases that are 
contracted person to person are limited when a critical proportion of the 
population or the herd immunity threshold is protected through vaccination or 
natural immunity to the infectious disease, thus reducing the potential 
prevalence or resurgence of the disease in the population (Plans-Rubio, 2014). 
Although there was not a strong linear relationship between the required or 
recommended immunization schedules and the incidence of pertussis, the fact 
that there was a significant relationship between the independent variables of 
required or recommended immunization schedules and the dependent variable of 
the incidence of pertussis supports the theory of herd immunity by verifying the 
relationship between vaccination and incidence.  
Research Question 2  
The data associated with Research Question 2 were analyzed utilizing 
Linear regression. The outcome of the linear regression analysis revealed that the 
null hypothesis had no association between the pertussis vaccine schedule that is 
required or recommended by the European country and the epidemiologic cycles 
of pertussis, for Research Question 2 was supported by the results. The 
alternative hypothesis that there is an association between the pertussis vaccine 
schedule that is required or recommended by the European country and the 
epidemiologic cycles of pertussis was not supported by the results and was 
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rejected. The data analysis found that there was not a significant relationship 
between the independent variable and the dependent variable.  
The linear combination of required and recommended immunization 
schedules was not significantly related to pertussis epidemiologic cycles in the 
European countries evaluated as part of the doctoral study. The coefficient of 
determination was .001. Therefore, the required or recommended immunization 
schedules are not a good predictor of the pertussis epidemiologic cycles in the 
European countries evaluated as part of the doctoral study.  
Although the required or recommended immunization schedules are not a 
good predictor of the pertussis epidemiologic cycles, the data obtained from this 
doctoral study does support findings from the research of Tan et al. (2015). Tan 
et al. (2015), suggested that the adolescent and adult populations are the most 
challenging to detect pertussis incidence due to the generalized characteristics 
and the lessened severity of pertussis in the adolescent and adult populations. 
The persistence of pertussis associated with the immune waning of the acellular 
vaccine in the adolescent and adult populations could account for the lack of 
relationship between the required or recommended immunization schedules and 
the epidemiologic cycles identified in this doctoral study.  
The lack of a relationship between the required or recommended immunization 
schedules and the pertussis epidemiologic cycles could suggest a low-level 
persistence of pertussis in the population caused by the immune waning of the 
acellular vaccines. The lack of a relationship between the immunization schedule 
types and the pertussis epidemiologic cycles would also support the theory of 
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herd immunity. If herd immunity in a population does not meet the required 
threshold, the herd effect will still provide a protective buffer of the population 
against the infectious disease (Holland & Chase, 2014).  
Research Question 3  
The data associated with Research Question 3 were analyzed utilizing 
linear regression. The outcome of the linear regression analysis revealed that the 
null hypothesis, that there is no association between the European country’s 
addition of recommended adolescent boosters to the pertussis vaccine schedule 
and incidence level of pertussis, for Research Question 3 be rejected. The 
alternative hypothesis, that there was an association between the European 
country’s addition of recommended adolescent boosters to the pertussis vaccine 
schedule and incidence level of pertussis, was supported by the results. Although 
there was not a strong linear relationship between the required or recommended 
immunization schedules and the incidence of pertussis, the data analysis found 
that there was a significant relationship between the independent variable and 
the dependent variable.  
The linear combination of the addition of a required or recommended 
adolescent booster was found to be significantly related to pertussis incidence in 
the European countries evaluated as part of the doctoral study. The coefficient of 
determination was .063, indicating that approximately 6.3% of the variance of the 
dependent variable pertussis incidence in the population can be accounted for by 
the linear combination of the two independent variables of required and 
recommended adolescent boosters. The addition of an adolescent booster to the 
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required or recommended immunization schedule has a stronger relationship to 
the incidence of pertussis than did the required or recommended immunization 
schedule without an adolescent booster. This finding supports the work of 
Gambhir et al. (2015), which concluded that there is a need for alternate 
vaccination schedules which would include adjustments to the age of vaccination, 
the age of booster doses, and cocooning strategies to help address the resurgence 
and persistence of pertussis. Additionally, the work of Radke et al. (2016) found 
that the vaccine protection from the immunization schedule only provides 
protection through age four. Further concluding that introducing a pertussis 
vaccine booster would enhance childhood immunity.  
The primary objective of pertussis immunization programs is the 
reduction of disease and the associated mortality, and the potential 
establishment of population herd immunity (Nitsch-Osuch et al., 2013). The 
linear combination of the addition of a required or recommended adolescent 
booster was found to be significantly related to pertussis incidence in the 
European countries evaluated as part of the doctoral study. Additionally, the 
inclusions of an adolescent booster to immunization schedule type has a stronger 
relationship to the incidence of pertussis than did the immunization schedule 
type without an adolescent booster. These findings support the work of Osuch et 
al., (2013). Osuch et al., (2013) concluded in their research that the adherence to 
vaccination schedules and use of appropriately timed boosters, when immunity 
against pertussis waning is suspected, are essential to the establishment of herd 
immunity (Nitsch-Osuch et al. 2013). Osuch et al. (2013) further concluded in 
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their research that the data provided evidence that European countries need to 
incorporate booster vaccinations into their immunization schedules to strengthen 
individual and population protection, and the establishment of strong herd 
immunity against pertussis infection and transmission (Nitsch-Osuch et al., 
2013). 
Research Question 4  
The data associated with Research Question 4 were analyzed utilizing 
Linear regression. The outcome of the linear regression analysis revealed that the 
null hypothesis that there is no association between the European country’s 
addition of required adolescent boosters to the pertussis vaccine schedule and the 
length of the epidemiologic cycles for Research Question 4 was supported by the 
results. The alternative hypothesis that there is there any association between the 
European country’s addition of required adolescent boosters to the pertussis 
vaccine schedule and the length of the epidemiologic cycles, was not supported by 
the results and was rejected. The data analysis found that there was not a 
significant relationship between the independent variable and the dependent 
variable.  
Although the addition of required adolescent boosters to the pertussis 
vaccine schedule and the length of the epidemiologic cycles did not show a 
relationship, the data obtained from this doctoral study do support findings from 
the research of Tan et al., (2015), as did the findings from Research Question 4. 
Tan et al. (2015) suggested that the adolescent and adult populations are the 
most challenging to detect pertussis incidence due to the generalized 
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characteristics and the lessened severity of pertussis in the adolescent and adult 
populations. As stated in the findings for Research Question 2, the persistence of 
the pertussis associated with the immune waning of the acellular vaccine in the 
adolescent and adult populations could account for the lack of relationship 
between the required or recommended immunization schedules with the addition 
of adolescent boosters and the epidemiologic cycles identified in this doctoral 
study.  
The lack of a relationship between the required or recommended 
immunization schedules and the pertussis epidemiologic cycles could suggest a 
low-level persistence of pertussis in the population caused by the immune waning 
of the acellular vaccines. The lack of a relationship between the immunization 
schedule types and the pertussis epidemiologic cycles would also support the 
theory of herd immunity. If herd immunity in a population does not meet the 
required threshold, the herd effect will still provide a protective buffer of the 
population against the infectious disease (Holland & Chase, 2014). However, it 
has been determined that the transmission of pertussis by adolescents and adults 
with waning pertussis immunity has caused the continuation of pertussis 
epidemiologic cycles in European countries (Heiniger et al., 2016). 
Limitations of the Study 
 There were several limitations to the generalizability and validity of the 
data associated with the doctoral study. One of the limitations was that the data 
presented in the WVPDMSGS database for several of the European Union 
countries had missing data associated with the timeframe of interest from 2010 
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to 2017. Because several of the countries were missing a significant number of 
data points, the countries were not included in the study. Therefore, the study 
results were not reflective of all of the European Union countries. Additionally, 
the data associated with the data set utilized for this doctoral study are presumed 
to be accurate, but there are factors that could threaten the data accuracy. 
Although the data is evaluated for accuracy and reliability, the entry of the data 
into the database and the compilation of the data from the various reporting 
sources could be a potential threat to validity, if they were not performed per the 
WHO and UNICEF prescribed principles. 
The validity of the data could also have been compromised if adequate 
reviews of the data were not performed by the WHO, UNICEF, local experts, and 
external reviewers. External validity threats also potentially exist associated with 
the WVPDMSGS database. External threats to the validity of the data being used 
to assess the research questions are the accuracy of the reporting and calculation 
of the immunization coverage from the participating member states. 
Additionally, biases could have been created if the participating member states 
failed to report portions of the population, or over or underestimated the 
vaccination coverage and incidence of the vaccine-preventable diseases.  
Recommendations 
 The results of the study suggested that there is a connection between the 
immunization schedule and the timing and requirement for pertussis 
immunizations. Additional research is required to more thoroughly examine the 
timing based on the age of the immunization schedules. Additionally, the data 
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from this doctoral study suggests that adolescent booster plays a role in 
contributing to the level of pertussis incidence in the European Union countries 
examined in this doctoral study. The addition of adolescent boosters to all 
pertussis immunization schedules, along with the timing and number of doses 
should be examined to determine the role that adolescent boosters contribute to 
the resurgence and persistence of pertussis.  
Implications for Professional Practice and Social Change 
The doctoral study results showed a relationship between immunization 
schedule types that were required or recommended on the incidence of pertussis. 
Furthermore, the immunization schedule types with the addition of an adolescent 
booster revealed a relationship associated with pertussis incidence rates. The 
data presented in this doctoral study also established a lack of a relationship with 
the immunization schedule type, required or recommended, and the design of the 
pertussis immunization schedule associated with epidemiologic cycles. The 
outcomes from this doctoral study, along with further research into the 
vaccination age and timing of the vaccinations associated with pertussis 
immunization schedules, could be applied in the field of public health to make 
significant improvements to pertussis immunization schedules to be used in the 
pertussis vaccination programs. The stated improvements to the pertussis 
immunization programs could reduce immune waning and, thus, lower the 
incidence of pertussis. 
The data generated from this doctoral study provides physicians and 
government health agencies with an enhanced understanding of the relationship 
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between the design and requirement of the immunization schedule on the 
incidence of pertussis and epidemiologic cycles. The data supports the need for 
the consideration of physicians and government health agencies regarding the 
implementation of required standardized immunization schedules, with the 
addition of an adolescent booster to the pertussis vaccination programs. The 
outcomes of this doctoral study also support the need to expand the research 
related to adolescent boosters and the role that they play in immune waning 
associated with acellular pertussis vaccines, along with the contribution that the 
immune waning has on the resurgence of pertussis.  
This doctoral study assisted in providing relevant data that contributes to 
the knowledge base associated with some of the potential factors that may be 
causative to the resurgence and persistence of pertussis. This enhanced 
knowledge of the potential relationship between the addition of adolescent 
boosters and the requirement or recommendation of the immunization schedule 
on pertussis incidence could assist in controlling the pertussis resurgence, reduce 
immune waning through the use of adolescent boosters, enhance immunization 
schedule timing, and lower the incidence of pertussis resulting in positive social 
change through improved immunization programs and disease control strategies.  
Conclusion 
Pertussis is a vaccine-preventable disease, but the incidence of the disease 
continues to rebound in countries with high vaccination rates (Esposito & 
Principi, 2016). The use of vaccines is an essential tool to protect public health 
against pertussis. Not only do vaccines protect the immunized individual, but 
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they also create a state of herd immunity that protects the population (Sabbe & 
Vandermeulen, 2016). Pertussis vaccines have played a protective role in 
reducing the incidence of pertussis. However, with the implementation of 
acellular vaccines, immunity is waning at a more rapid rate than with whole-cell 
vaccines (Sabbe & Vandermeulen, 2016).  
The focus of this doctoral study was to gain an understanding of the 
potential relationship between the pertussis vaccination schedule, whether 
recommended, required, with an adolescent booster or without an adolescent 
booster, and the European country’s pertussis incidence and epidemiologic 
cycles. The study findings suggest that the pertussis immunization, whether 
recommended or required, does have an influence on the incidence rate of 
pertussis within the populations of European countries analyzed as part of this 
doctoral study. The same influence on pertussis incidence was demonstrated 
related to recommended or required adolescent boosters as part of the pertussis 
immunization schedule. 
The doctoral study data also revealed that the pertussis immunization, 
recommended or required, does not have a significant relationship with the 
epidemiologic cycle of pertussis within the populations of European countries 
analyzed as part of the doctoral study. The same lack of relationship on the 
epidemiologic cycle of pertussis was demonstrated related to recommended or 
required adolescent boosters as part of the pertussis immunization schedule. 
This doctoral study assisted in providing relevant data that contributes to 
the understanding of the association with some of the potential factors that may 
69 
 
 
 
be contributing to the resurgence and persistence of pertussis. Additionally, the 
data generated from this doctoral study provides an enhanced understanding of 
the relationship between the design and requirement of the immunization 
schedule on pertussis incidence. This enhanced understanding of the potential 
relationship between the design and requirement of the immunization schedule 
on pertussis incidence could assist in controlling the pertussis resurgence, reduce 
immune waning through the use of adolescent boosters, enhance immunization 
schedule timing, and lower the incidence of pertussis resulting in positive social 
change through improved immunization strategy.  
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